HMGCR and Alzheimer disease: Several clinical trials associated statins, inhibiting the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and, thus, cholesterol de novo synthesis, with a diminished risk to AD [22,23,24], whereas other clinical studies showed no differences [25,26,27].